News

Latest News

Advocacy in Action: September 26

September 26, 2023
 
  

What's happened

September 1, Roundtable on Improving Canada’s Medical Countermeasure Readiness for Health Emergencies 

CPO Rita Dhami participated in a roundtable with Deputy Minister Stephen Lucas and spoke on how to improve Canada's medical countermeasure preparedness for future health emergencies. Rita covered hospital pandemic preparedness plans including interdepartmental key accountabilities and critical paths. Additionally, she stressed the importance of coordination among all healthcare providers across Canada, as well as the importance of public communication and education. 

September 12, Appropriate Use Advisory Committee Interim Report Roundtable 

A unified appropriate-use program is being developed by the Canadian Drug Agency (CDA) to improve the pharmaceutical landscape. During this interim report roundtable, Rita spoke about the importance of promoting evidence-based approaches and interventions to improve the pharmaceutical industry. In addition to identifying drivers of inappropriate use, hospital pharmacy teams also employ multi-pronged behaviour change strategies in order to improve prescribing. 

September 14, European Association of Hospital Pharmacists meeting 

Canadian Society of Hospital Pharmacists (CSHP) President Sean Spina, CEO Jody Ciufo, and CPO Rita Dhami met with Ambassadors from the European Association of Hospital Pharmacists (EAHP) where EAHP introduced their organization and its strategic priorities. Over the course of this meeting, both organizations found several areas of overlap in their work including a shared focus on vision for practice, drug shortages, sustainability, and human resource challenges. It is expected that this meeting will be the first of many collaborations between CSHP and EAHP.

Ongoing, Health Canada Drug Shortages meetings

CSHP is providing weekly feedback and amplifying the voice of hospital pharmacy on drug shortages.

  • Sept. 15: Multi-Stakeholder Call #2 – Supply disruptions of Ozempic 
  • Sept. 20: Multi-Stakeholder Call #12 – Shortages of Amoxicillin Oral Suspension/Capsules/Tablets

What's happening 

September 25, Canadian Nosocomial Infection Surveillance Program

CSHP will be attending a meeting regarding the Canadian Nosocomial Infection Surveillance program, a collaboration between the Public Health Agency of Canada (PHAC) and the National Microbiology Laboratory (NML), which will be addressing the program’s Antimicrobial Medication Use data in hospitals. The meeting will also highlight protocols and current advocacy to bring new antimicrobials to Canada. As advocates for antimicrobial stewardship, CSHP looks forward to being updated on these topics and their impact on hospital pharmacy.  

What's worth repeating

August 30, Drug Shortages Consultation has been submitted

CSHP’s submission provided four fundamental pillars that serve as a blueprint for collaborative action between Health Canada and fellow stakeholders. View the submission here.

To catch up on CSHP advocacy news, click here.

Have a question about Advocacy in Action or CSHP's advocacy and consultation work?
Reach out to our professional practice team!   

September 26, 2023
Advocacy in Action: September 26

Latest News

APOthecary Heroes Contest

Sept. 25, 2023
Apotex has launched its APOthecary Heroes Program and is now accepting nominations! This program reinforces the critical role Canada’s Pharmacy Professionals play in improving patient health. Increasingly the impact of these front-line healthcare providers is being recognized, most recently with expanded prescriptive powers and administering abilities in many provinces. The APOthecary Heroes Program is Apotex’s way of honouring them for their continued efforts to strengthen the Canadian healthcare system.

The program is open to anyone in Canada, including Pharmacists, Pharmacy Technicians, Pharmacy Assistants, Students, and Interns, who have demonstrated excellence in their role and made a significant impact on their community.

Nominate a colleague or yourself to be an APOthecary Hero today! Click here to nominate—it’s quick and easy! Program closes October 25th.

 

September 25, 2023
APOthecary Heroes Contest 2023

Latest News

Student Member Stories: Raymonda Zheng

September 10, 2023
 
 

About Raymonda

Pronouns: She/Her/They/Them
School, Program & Year: University of Saskatchwan, PharmD, fourth year
Social media: Raymonda Zheng on Linkedin

What is enticing to you about hospital pharmacy?

I enjoy working in a fast-paced environment where I challenge myself to be a more well-rounded healthcare professional. Hospital pharmacy gives me the adrenaline I need to achieve my potential to provide optimal patient care while also providing me with meaningful connections with patients and families. The interdisciplinary collaboration in hospital pharmacy allows me to work alongside and be inspired by excellent clinicians with diverse backgrounds, knowledge, skills, and perspectives. This collaborative approach aids me in improving my own practice continuously and engaging in patient-centred and informed decision-making where all aspects of a healthcare team are considered. 

What drew you to join CSHP as a student?

At every orientation for the new school year, our CSHP student reps present what CSHP is to the student body of the college. They were great at advertising, and I was sold! As an international student who was not familiar with the Canadian healthcare system, I joined CSHP to become part of a community that values professional development and innovation and commits to excellence in patient care. CSHP aligns with my beliefs and provides me with resources to support my professional growth.

How do you see yourself reflected by CSHP?

I see myself reflected in CSHP through the commitment to patient care excellence and the platform of collaboration. I feel grateful to be mentored by many CSHP members who inspired me on my journey as a pharmacy student. I’ve worked with resident, pharmacist, and technician members who all strived for shared value. I wish to give back to the community as a practicing pharmacist to guide students in the future, just like those who guided me. 

Have you ever attended or presented at a CSHP event?

I have remotely attended webinars hosted by the national and provincial branches to deepen my understanding of knowledge learnt in school and to keep up with the ever-updating health guidelines. The sessions were very informative hosted by pharmacists across Canada, so I also got to educate myself on the scopes of pharmacists in different provinces and in different hospital settings. As I relocate to BC this fall for an APPE rotation, I will be attending the BC clinical symposium.

What is one CSHP resource or benefit that you couldn’t live without?

As I start thinking about my career path upon graduation next May, the residency roadmap course helps me to navigate through the residency application process. I would recommend all graduating pharmacy students to watch the free first module to consider if hospital pharmacy would be an option for them.

What is one piece of advice you give soon-to-be pharmacy students?

Don’t hold yourself back. Seek mentorship and explore a diversity of opportunities. The field of pharmacy is constantly evolving. Find your passion, take chances, and discover what unfolds!

Anything else you'd like to say to the CSHP members reading this?

I appreciate the community that CSHP and our members have built. I hope we all continue to inspire one another and endeavour to deliver exceptional patient-centred care.

 

Want to share your student story?
Tell us about yourself here for a chance to be featured.

September 10, 2023
Student Member Stories: Raymonda Zheng

Clinical Pearls: Environmental sustainability in pharmacy curriculum - A PharmD student’s perspective  

September 8, 2023
By Holly Wingate 
 
This article is part of a series appearing in Interactions, our biweekly newsletter, written and researched by CSHP's students. We've created this series as a valuable learning activity for pharmacy students undertaking rotations at CSHP. Crafting these pieces not only helps students gain in-depth knowledge of specific conditions, treatments, and resources, it also helps them hone their skills in research, critical appraisal, evaluation, synthesis, and writing – all of which will serve them well in clinical practice. The Professional Practice Team works with the students to select hot topics that are of interest and utility to both the students and to you, the reader. We hope you enjoy this piece by one of our future colleagues! Let us know what you think. If you would like to provide any comments or constructive feedback for our students, please email us at practice@cshp.ca.
 

Climate change: Background

While not a new concern, climate change is becoming more recognizable across the world, with extreme storms, forest fires, and more. For example, air pollution is the greatest environmental risk to health as nine out of ten people breathe polluted air every day, which kills 7 million people/year.1 The harmful effects of air pollution manifest in lung cancer, stroke, allergy, chronic obstructive pulmonary disease (COPD), asthma, and heart disease, among other health problems.1 These emissions are responsible for more than 25% of deaths from heart attack, stroke, lung cancer, and chronic respiratory disease globally.2  As we step back and look at these statistics from a health care professional lens and see the clear link between the environment and patient health, one can see the immense amount of work ahead to decrease pharmaceutical impacts on the climate and in turn, on our patients. For example, researchers estimated that health care emissions between 2009-2015 resulted in 23,000 years of life lost due to disability or early death.3 

As we shift viewpoints towards healthcare, we see that hospitals and pharmaceutical companies are two of the biggest drivers of emissions.3 Medicines are the most common intervention in healthcare, accounting for roughly 25% of carbon emissions within the NHS.4 In Canada, our healthcare systems are responsible for 5% of all greenhouse gas emissions within the country, and pharmaceuticals comprise 25% of these.4  If we consider the entire life cycle of a medicine, from design and development, marketing authorization to production, post-authorization, health technology assessment, prescription, consumption and finally waste disposal, pharmacy can have an impact at every stage.5  For example, certain inhalers account for around 3% of these emissions.5 Perhaps, if more pharmacy professionals were aware of the environmental impacts and actively encouraged environmentally friendlier alternatives, we may be able to mitigate some of these effects. 

Training the upcoming generation of pharmacy professionals

In Canada, the PharmD and Pharmacy Technician program curricula’ are mandated by the Canadian Council for Accreditation of Pharmacy Programs (CCAPP). For PharmD programs, curriculums must include foundational content in areas such as biomedical, pharmaceutical, behavioral, social, and administrative pharmacy sciences, as well as teaching clinical sciences including clinical practice skills, and intra- and inter-professional collaborative practice skills.6  Also required is a total of a minimum of 40 weeks of practice experience, of which 32 weeks must occur near the end of the program.6 In pharmacy technician programs across Canada, foundational content requirements are similar; however, there is more focus on product distribution, calculations, and communication practices, among other skills. Alongside this, is a required minimum of nine weeks' practium.7 Additionally, curricula are based off the Canadian Pharmacy Technician Educators Association’s (CPTEA) nine educational outcomes, which include Professional, Provider of Care, Contributor to a Safe, Effective, and Efficient Practice Setting, Knowledgeable Professional, Communicator and Educator, Contributor to Quality and Safety, and Roles in Product Distribution, Health Promotion, and Intra- and Inter-Professional Collaboration.8 For PharmD programs specifically, the curriculum is free to be modified as long as CCAPP requirements are met, and curricular content demonstrates competency in the 7 educational outcomes created by the Association of Faculties of Pharmacy of Canada (AFPC).The AFPC provided these updated educational outcomes for PharmD programs in 2010, stating “The revised educational outcomes are formatted with the overall goal of graduating Medication Therapy Experts.” Emphasis is placed on the multiple roles of graduates through explicit statements within the appropriate outcome.9 These outcomes include Care Provider, Communicator, Collaborator, Manager, Advocate, Scholar, and Professional.9 

In my fourth year of my PharmD program, I frequently reflect on all I have learned in my short few years within Pharmacy. I feel my professionalism and clinical knowledge has increased substantially; however, as I look at the environment around me in which I am supposed to live and work, and see the impact from pharmaceuticals, I feel a large knowledge gap in how to improve my impact here. At present, there is no consensus or mandatory requirements among pharmacy schools in Canada, or elsewhere in the world, detailing the specific environmental sustainability competencies and skills a pharmacist should possess.3 Neither the AFPC nor CCAPP mandate any sustainability measures in PharmD or Pharmacy Technician students. As I head to graduation, I worry that this lack of knowledge may impact the upcoming generation of pharmacy professionals more than expected, as the effects of climate change on our patients becomes abundantly clear. 

My thoughts on why it is important for students to be taught environmental sustainability   

Pharmacists have a duty to their patients to be educated and up to date on therapies and healthcare treatments; however, when it comes to issues surrounding the environment there is an overall lack of training, despite a clear link between patient health and the environment. When we look at who climate change impacts the most, our most vulnerable patients are at the greatest risk of feeling its effects, and in turn, its effects on their health. Knowing the large carbon footprint of pharmaceuticals and how pharmacists are experts on how medications affect patients, they are uniquely positioned and skilled as trusted health care professionals and clinical leaders to take a leadership role in the environmental movement.10 However, overall, there is a lack of awareness among pharmacists in respect to pharmaceutical impacts on climate change, signifying an increased need for environmental training within the profession.11 This includes students, as they want to learn, and engage in prioritizing sustainable practices for their future careers.3 Training our students, who will advance to many different careers within pharmacy, will ensure that effective mitigation strategies reach all ends of the profession.12   

On a personal level, though my experiences with the world are limited, I have already felt an impact from climate change, even if I didn’t call it that at the time. Across Canada, we’re seeing and feeling extreme weather, including forest fires reaching all ends of the country with their smoke. The effects of climate change are ones that all students, regardless of background or place in the country, will experience in some sort of way, and will be the catalyst for change. This is based on the fact that education is an effective method to changing behaviour, as long as there is a deep connection or personal relevance to the issue being taught.13 Now that I have completed the classroom learning component of my pharmacy education, and as I think of my future career, I feel education in environmental sustainability would have changed how I consider medications for patients and would have been a valuable addition to the PharmD education I received. Aside from professional reasons, I think learning about how pharmacy impacts the environment, and how the environment impacts our health, would have been incredibly enlightening for me as a person. Afterall, I am going to be living on this planet for quite a few more years if I’m lucky; I’d like it to last that long for me. 

Though Canada is lacking in sustainability teachings, especially for pharmacy students, many places around the world have begun this training for students. Although not a pharmacy specific example, it shows the impact of this type of education on students in the long run. At San José State University in California, students from different colleges, including humanities, business, and sciences, were taught core themes of climate science, climate mitigation and environmental communication, in a one-year course.13 The effects on students’ behaviour after this course were then assessed through a survey, a minimum of 5 years afterwards. Findings showed that graduates reduced their individual carbon emissions by 2.86 tons of CO2 on average each year, and described a strong connection to climate change solutions, both personally and professionally.13 A majority of participants also agreed that global warming would affect their lives, that they’ve already experienced the effects of global warming, and that it will have a large impact on future generations.13 This type of educational opportunity allowed each of these students to take what they learned into their personal and professional lives, and the education translated into behavioural changes, likely due in part to the personal connection everyone shares with climate change. The effect of the course may be extrapolated to pharmacy students as the students in the study were from different backgrounds and colleges but showed similar changes in behaviour. 

There are some specific pharmacy programs which have begun incorporating sustainability into student training. For example, the University of Huddersfield in Queensgate, United Kingdom, began consciously teaching environmental sustainability in the MPharm curriculum in 2021, with the key role of delivering future pharmacists who will be best placed and ready to play their part in fighting climate change.14 After the National Health Service (NHS) made public their efforts towards becoming NetZero, pharmacy faculty at the University of Huddersfield decided that refocusing their MPharm curriculum through an environmental sustainability lens was needed, to ensure students were as prepared as possible at graduation, especially considering the huge contribution medicines have on the environment.14 This being said, no new curricular content was introduced, as what students needed to learn was already present within the existing curriculum.14 The University of Huddersfield is a great example of how pharmacy curricula across the globe can incorporate sustainability into pharmacy teachings and is a great starting place for Canadian PharmD and Pharmacy Technician programs to begin such change as well. 

How to advocate for this as a profession

Although education on pharmaceuticals, climate change and environmental sustainability are likely to be absent in pharmacy curricula for a few more years, as a profession we have an opportunity to advocate, encourage and support our students in this learning. We need to become knowledgeable and/or maintain our knowledge on the effects of climate change, how pharmacy plays a part, and know which resources are available to you and those around you. This starts with a personal reflection on climate change; knowing how it has personally impacted you in your life forms the personal connection which will encourage behavioural changes that can translate into professional practice. Professionally, you can participate in continuing education opportunities such as webinars and online courses, which focus on sustainability education. You can also reflect on how your practice could improve its’ impact on the environment. For example, knowing how a patient’s medications impact the environment is a great place to start learning. For more information about the environmental impact of inhalers specifically, please see CSHP’s recent Clinical Pearl: Environmental Impacts of Inhalers. As pharmacy professionals, we need to use our voice to advocate for more sustainable practices and paperless formats in our workplaces to minimize operational waste.15

Starting with yourself is the best actionable measure to ensure this movement continues. However, taking the opportunity while precepting, lecturing, or talking to students, to initiate conversations on environmental sustainability and encourage life-long learning early on, can make the difference in the spread of sustainability practices in pharmacy. Ensure you have resources on-hand to share with students so they can start their personal sustainability journey. Stay tuned for our Resource Spotlight for more information on these specific resources.  

References

  1. FIP Call To Action: Mobilising Pharmacists Across Our Communities to Mitigate the Impact of Air Pollution on Health. International Pharmaceutical Federation; 7 Sep 2021. Available from: https://www.fip.org/file/5024  
  2. Urgent health challenges for the next decade. World Health Organization; 2020. Available from: https://www.who.int/news-room/photo-story/photo-story-detail/urgent- health-challenges-for-the-next-decade  
  3. Mercer C. How health care contributes to climate change. Canadian Medical Association Journal (CMAJ). 2019;191(14):E403-E404. doi:10.1503/cmaj.109-5722 
  4. Mathers A, Fan S, Austin Z. Climate change at a crossroads: Embedding environmental sustainability into the core of pharmacy education. Canadian Pharmacists Journal/ Revue des Pharmaciens du Canada. 2023;156(2):55-59. doi:10.1177/17151635231152882  
  5. Pharmacy’s Role in Climate Action and Sustainable Healthcare. Royal Pharmaceutical Society of Great Britain; 2023. Available from: https://www.rpharms.com/recognition/all-our-campaigns/policy-a-z/pharmacys-role-in-climate-action-and-sustainable-healthcare  
  6. ACCREDITATION STANDARDS for CANADIAN FIRST PROFESSIONAL DEGREE IN PHARMACY PROGRAMS. The Canadian Council for Accreditation of Pharmacy Programs; 2018 (Revised 2020). Available from: https://ccapp.ca/wp-content/uploads/2020/10/July7-CCAPP-Professional-Standards-ENG.pdf  
  7. ACCREDITATION STANDARDS FOR CANADIAN PHARMACY TECHNICIAN PROGRAMS. The Canadian Council for Accreditation of Pharmacy Programs; 2019 (Revised 2020). Available from: https://ccapp.ca/wp-content/uploads/2020/10/2020-PT-CCAPP-PharmTech-Standards_ENG.pdf  
  8. Educational Outcomes for Pharmacy Technician Programs in Canada. Canadian Pharmacy Technician Educators Association (CPTEA); 2017. Available from: https://cptea.ca/media/files/files/081ad2cf/cptea-2016-final-revised-document-february-10-2017.pdf 
  9. Educational Outcomes for First Professional Degree Programs in Pharmacy (Entry-to-Practice Pharmacy Programs) in Canada. Association of Faculties of Pharmacy of Canada (AFPC); 2010. Available from: https://www.afpc.info/sites/default/files/AFPC%20Educational%20Outcomes.pdf  
  10. Roy C. The pharmacist's role in climate change: A call to action. Can Pharm J (Ott). 2021;154(2):74-75. Published 2021 Feb 10. doi:10.1177/1715163521990408 
  11. Tai BW, Hata M, Wu S, Frausto S, Law AV. Prediction of pharmacist intention to provide medication disposal education using the theory of planned behaviour. J Eval Clin Pract. 2016;22(5):653-661. doi:10.1111/jep.12511 
  12. Self E. Universities must teach future pharmacists about protecting the environment. The Pharmaceutical Journal; 15 Sep 2021. Available from: https://pharmaceutical-journal.com/article/opinion/universities-must-teach-future-pharmacists-about-protecting-the-environment 
  13. Cordero EC, Centeno D, Todd AM. The role of climate change education on individual lifetime carbon emissions. PLoS ONE 2020;15:e0206266. doi:10.1371/journal.pone.0206266  
  14. ‘Greening’ the MPharm: embedding environmental sustainability in the curriculum. The University of Huddersfield; Oct 2021. Available from: https://www.hud.ac.uk/news/2021/october/embedding-environmental-sustainability-in-pharmacy/  
  15. Miller J. Pharmacy sustainability: What is our role? American Pharmacists Association (APhA); 11 Nov 2021. Available from: https://www.pharmacist.com/Publications/Transitions/pharmacy-sustainability-what-is-our-role

 

Latest News

September 08, 2023
Clinical Pearls: Environmental Sustainability in Pharmacy Curriculum: A PharmD Student’s Perspective

Latest News

CSHP at the Canada Healthcare Innovation Summit

September 7, 2023
 
 

Join CSHP CEO Jody Ciufo at the Canada Healthcare Innovation Summit!

Join CSHP CEO Jody Ciufo as she moderates the Canada Healthcare Innovation Summit’s panel “Innovation in Pharmaceutical and Therapeutic Management”. This panel will include experts like Michael Stacey, Executive Vice President (Academic) & Chief Medical Executive, Hamilton Health Sciences, Gerald Batist, Director, Segal Cancer Centre at Jewish General Hospital and McGill University, Jennifer Zelmer, President & CEO, Healthcare Excellence Canada, and John Adams, Board Chair, Best Medicines Coalition. 

Learn more about the summit below and reserve your tickets here


Introduction

The Canada Healthcare Innovation Summit 2023! This highly anticipated event brings together healthcare stakeholders from across the country to explore the latest advancements in digital healthcare. The summit provides a platform for healthcare professionals, innovators, regulators, government officials and clinicians to share insights and expertise on the most pressing issues facing the healthcare innovation in Canada.

Main topics

  • New challenges in healthcare management
  • Innovation and future infrastructure for hospitals
  • Health digital transformation
  • Therapeutic innovation

Target audience

The target audience for this event is diverse, including:

  • Regulators and government officials: representatives from the Ministry of Health, Territorial and Regional Health Authorities as well as other government agencies involved in healthcare policy and regulation.
  • Innovators: entrepreneurs and startup companies working in the field of healthcare technology and innovation.
  • Clinicians: medical professionals from a variety of specialties, including oncologists, cardiologists, radiologists, and others.
  • Healthcare executives: leaders and decision-makers from hospitals, health systems, and other healthcare organizations.
  • Researchers and academics: scientists and scholars studying healthcare innovation and technology.
  • Industry professionals: representatives from pharmaceutical, biotech, and medical device companies.

By bringing together such a diverse group of stakeholders the summit aims to collaborate on solutions to the challenges facing Canada's healthcare system. The audience has the option to attend in person or virtually, using the live comment and networking area of our platform to interact and to ask questions during the panels. Meanwhile all panelists will be present on site.

Attendees will have the opportunity to learn from experts in the field, network with other professionals, and discuss strategies for improving healthcare in Canada. With a focus on digital transformation, therapeutic innovation, smart hospital infrastructure, and artificial intelligence and big data, attendees can expect to leave the summit with valuable insights and ideas to enhance healthcare delivery in Canada.


Register today

September 07, 2023
CSHP at the Canada Healthcare Innovation Summit

Latest News

CPRB News - September 2023

September 7, 2023
 
 
 

Survey update - September 2023


CPRB Surveyor Group Members  
  • Leslie Manuel* — Moncton, NB
  • Cathy Burger — Hamilton, ON
  • Roxane Carr* — Vancouver, BC
  • Barb Evans — Saskatoon, SK
  • Jean Lefebvre* — Québec, QC
  • Curtis Harder — Victoria, BC
  • Christine Landry* — Ottawa, ON
  • Marc Perrault — Montréal, QC
  • Erika MacDonald — Ottawa, ON
  • Barb Thomas — St. John's, NL
  • Amy Marriott — Toronto, ON 
  • Jennifer Bolt — Kelowna, BC
  • Bonnie Ralph — Kingston, ON
  • Gisia Pisegna — Moncton, NB
  • Rhonda Roedler — Calgary, AB

*Current CPRB member

New members
The group is pleased to welcome our newest members Bonnie Ralph, Amy Marriott, and Rhonda Roedler. Their expertise and commitment will undoubtedly contribute to the success of the group's mission.
 
Overview of CPRB Surveyor Group
CPRB surveyor group is comprised of residency program directors, coordinators, or preceptors of CPRB-accredited programs from each province that has residency programs. The primary objectives include: 
  • Recruit and train a pool of surveyors to conduct site surveys of pharmacy residency programs
  • Participate in 1-2 accreditation survey visits yearly
  • Review and propose updates to survey documents to CPRB
  • Identify, based on survey findings, any clarifications or changes required to the Accreditation Standards and sharing these with the Standards Group
  • Identify, based on survey findings, any educational opportunities, and sharing these with the CPRB and CSHP


Survey Activities
In terms of our survey activities, the group typically evaluates 8-12 programs annually. The number of programs surveyed depends on various factors, such as geographic locations, the number of residents, and the number of sites within each program. This spring, the group successfully surveyed 6 programs, and is gearing up to survey 4 more programs this fall.

The dedication and commitment of the surveyors to maintaining high standards within pharmacy residency programs across Canada are truly commendable. We look forward to continuing our collaborative efforts to ensure excellence in pharmacy education and training.

September 07, 2023
CPRB News - September 2023

Latest News

Call for resolutions: 2023 Annual General Meeting

August 28, 2023

Through the process of submitting written resolutions, CSHP members have the opportunity to present issues for discussion by the membership at the Annual General Meeting (AGM).

The next AGM will be held in-person and via Zoom on Saturday, October 22, 2023, at 11:00 am. Resolutions will be accepted from voting members of CSHP.

Please submit your resolutions in writing by Friday, September 15, 2023, to Hira Tauqeer, CSHP's Corporate Coordinator, at htauqeer@cshp.ca or mail to 30 Concourse Gate, Unit 27, Ottawa, ON K2E 7V7.

To obtain CSHP’s Resolution Submission Form with guidelines for developing a resolution, contact Hira at the national office at htauqeer@cshp.ca

CSHP’s Resolution Policy:  A resolution is a formal, written motion, usually used to address important or complex questions, or when greater formality is required.  A resolution usually includes the reasons for the motion (background) as well as the action that is being proposed. 
Resolutions to be presented at the 2023 AGM must be submitted by September 15, 2023.
 
August 29, 2023
Call for resolutions: 2023 Annual General Meeting

Latest News

Advocacy in Action: August 29

August 29, 2023
 
  

What's happened

August 22, Roundtable meeting with Assistant Deputy Minister Stefania Trombetti

CEO Jody Ciufo and CPO Rita Dhami participated alongside Assistant Deputy Minister for Health Canada, Stefania Trombetti, the National Association of Pharmacy Regulatory Authorities (NAPRA), and the Canadian Paediatric Society. Solutions to improve access to drugs and other healthcare products in Canada were discussed. CSHP highlighted key aspects of our drug shortages consultation (read below).

August 23, Canadian Medical Association (CMA) 'Net Zero' meeting

Rita Dhami met with CMA Lead Sarah Lowden to explore collaboration opportunities to achieve a more sustainable healthcare system. 

August 24, Canadian Healthcare Workforce Network meeting 

Ivy Bourgeault and Dr. Natalie Crown, Project Leads of Health Human Resources initiatives, met with Rita to discuss their success in developing a toolkit to help health workers cope with burnout and an upcoming research opportunity pertaining to pharmacy health human resources.

August 25, Letter to Hon. Minister of Health Mark Holland

Jody Ciufo’s letter introduces CSHP and conveys the Society’s commitment to working with Minister Holland to promote the highest standards of healthcare and patient well-being in Canada.

Ongoing, Health Canada Drug Shortages meetings

CSHP is providing weekly feedback and amplifying the voice of hospital pharmacy on drug shortages

  • Aug 16: Multi-Stakeholder Call #11 – Shortages of Amoxicillin Oral Suspension/Capsules/Tablets 
  • Aug 23: Multi-Stakeholder Call – Impending supply disruptions of Ozempic 
  • Aug 24: Tier Assignment Committee Meeting – Potassium Chloride, Calcium Chloride, Dextrose 50% 
  • Aug 25: Tier Assignment Committee Review – Hydralazine and Primene 10% 

What's happening 

August 30, Drug Shortages Consultation to be submitted

CSHP’s submission provides four fundamental pillars that serve as a blueprint for collaborative action between Health Canada and fellow stakeholders.

  • Improved communication and transparency
    • Improved two-way communication and transparency from hospitals and manufacturers 
    • Earlier identification process for shortages and turn-around to Tier Assignment Committee 
  • Agile regulatory toolbox
    • Reassessment of outsourced drug preparation (previously known as commercial compounding) legislation to inform where compounding can support shortages 
  • Greater supply chain visibility  
    • Development of harmonized barcoding standards 
  • Enhanced response to supply and demand
    • Coordination of collaboration between CSHP and Medical Organizations to develop tools/resources to support hospital clinicians during shortages
    • Development of ethical framework to respond to shortages and prioritize patients consistently 

What's worth repeating

Tier 3 shortage: Hydrocortisone Injections

On August 2,  Solu-Cortef® was deemed a Tier 3 shortage and was posted on the Tier 3 drug shortages list. While the shortage of the 100mg strength has ended and the estimated end dates for the 500mg and 1g injections remain the same, the 250mg shortage has been extended to September 11.

To catch up on CSHP advocacy news, click here.

Have a question about Advocacy in Action or CSHP's advocacy and consultation work?
Reach out to our professional practice team!   

August 29, 2023
Advocacy in Action - August 29

Latest News

Resource Spotlight: Tirzepatide and Upcoming Medications

August 29, 2023
 

Written by Holly Wingate

This article was written and researched by a CSHP student member for Interactions, our biweekly newsletter. Crafting these pieces not only helps students gain in-depth knowledge of specific conditions, treatments, and resources, it also helps them hone their skills in research, critical appraisal, evaluation, synthesis, and writing – all of which will serve them well in clinical practice. The Professional Practice Team works with the student to select topics that are of interest and utility to both the student and to you, the reader. We hope you enjoy this piece by one of our future colleagues! Let us know what you think: If you would like to provide any comments or constructive feedback for our students, please email us at practice@cshp.ca

Background

Tirzepatide (Mounjaro) is a recently approved selective glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist (RA).2 Tirzepatide has shown benefits for achieving glycemic control, including reductions in HbA1C and blood glucose control, with varying degrees of weight loss and without hypoglycemia, across various SUPRASS trials.This was seen across trials as monotherapy, in combination with metformin, an SGLT2i, or basal insulin, and through comparisons with placebo, semaglutide, and basal insulin.1 It is indicated as a once-weekly therapy as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus (T2DM), and there are trials currently underway for obesity (SURMOUNT trials) and heart failure with preserved ejection fraction (HFpEF) (SUMMIT trial). This “Resource Spotlight” contains tools for staying up to date with upcoming therapies as health care professionals, as well as tirzepatide specific resources. To learn more about tirzepatide and its place in Type 2 Diabetes treatment, check out the Canadian Society of Hospital Pharmacists (CSHP) recent Clinical Pearl article on Tirzepatide here.

 

Upcoming medications resources

Canadian Journal of Health Technologies (CJHT)
The CJHT is an open-access online scientific and policy journal that is published by the Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH is a not-for-profit organization which is funded by Canada’s federal, provincial and territorial governments. It provides health care decision-makers with independent evidence, advice, and recommendations to help inform policy and practice decisions. Each month, the CJHT produces articles such as horizon scans, reimbursement reviews, and health technology assessments. For example, the current May 2023 issue has 3 reimbursement reviews, 1 horizon scan, and 2 health technology reviews published at the time of writing. Their horizon scans describe new medications, tests, or treatment considerations for differing conditions, and are useful for staying up to date on upcoming treatments which may affect practice. Click here to see the most recent horizon scan on Objective Assessment System for Cognitive Function.

ClinicalTrials.gov
ClinicalTrials.gov is a web-based resource maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH), which provides open access to information on publicly and privately supported clinical studies under a wide range of diseases. The website features the Find Studies tab which enables the reader to See Studies by Topic, which then provides a list of all systems with trials currently underway or completed, such as Behavioural and Mental Disorders, Eye Diseases, Infections, Neoplasms, Substance Related Disorders, Wound and Injuries, and more. You can choose which system to look into and sift through trials based on the specific condition listed. For new medications or those with expanded indications being trialed, using raw trial data can help form independent opinions of the indication and clinical significance of the trial when looking at the population included, inclusion and exclusion criteria, duration, primary outcomes and results. Click here to access the Search by Topic resource.

Tirzepatide resources 

American Diabetes Association: Standards of Care in Diabetes
In this supplemental PDF from the ADA’s guidelines, tirzepatide’s place in the treatment of type 2 diabetes is described. Under the Journal of Clinical and Applied Research, the ADA aims to promote better patient care by serving the expanded needs of all health professionals committed to the care of patients with diabetes. This guideline is highlighted as there is no Canadian data for tirzepatide at the time of writing, therefore extrapolating the use of tirzepatide to Canadian patients, as well as its place in diabetes treatment, is required. On page 155 of this document, the flow-chart ‘Use of Glucose-Lowering Medications in the Management of Type 2 Diabetes’ provides a comprehensive approach to determining which patient may have the most benefit from Tirzepatide. Table 9.2 on page 156 provides detailed comparison of anti-hyperglycemic medications that may be useful for deciding which medication to choose based on patient-specific characteristics and comorbidities (such as CKD, HF, or sensitivity to side effects). Click here to see the Use of Glucose-Lowering Medications flow-chart, and here for Table 9.2.

CADTH Horizon Scan: Tirzepatide 
This CJHT horizon scan was published in their April 2022 issue before tirzepatide’s eventual approval in November of 2022. This resource is highlighted due to its comprehensiveness in background and trial information, as well as its references listed. The SURPASS trials are described in comparison with each other, and then in more comprehensive detail on their own, offering a complete look at each trial specifically. While not described in detail, all SURMOUNT and SUMMIT trial reference links are included as well. Click here to read the horizon scan on Tirzepatide for Type 2 Diabetes Mellitus.

Tirzepatide Review Articles
As tirzepatide is a fairly new drug, especially in Canada, there are little guideline recommendations to follow; when looking at the ADA guidelines, although able to decipher where tirzepatide falls into the classes of T2DM medications, it is not clearly laid out when to initiate the medication, and this can only be extrapolated to a certain extent for Canadian patients. Below are some useful review articles when trying to determine which patient tirzepatide is most ideal in, and to summarize tirzepatides characteristics:

  1. Lingvay I, Cheng AY, Levine JA, Gomez-Valderas E, Allen SE, Ranta K, et al. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes Obes Metab. 2023;25(4):965-974. doi:10.1111/dom.14943. This post hoc analysis only reviews the SURPASS 1-5 trials, thoroughly compares the trial designs to each other including participants and end points. This article is included as it is a good starting point to form one's own opinions on tirzepatides benefits. The full article can be found here.
  2. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. Published 2022 Jul 5. doi:10.3390/molecules27134315. This article presents the key characteristics of tirzepatide in terms of synthesis, structure, and activity, bearing in mind its advantages and shortcomings. Authors also briefly review the key clinical trials. Click here to review the article.
  3. Gallwitz B. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front Endocrinol (Lausanne). 2022;13:1004044. Published 2022 Oct 13. doi:10.3389/fendo.2022.1004044. This article summarizes the current clinical study programs (SURPASS and SURMOUNT) and the respective outcomes and highlights further potential indications for tirzepatide in the treatment of obesity and potentially other comorbidities of T2DM. It also describes the clinical use and benefits of dual incretin agonists. Click here to review the article.
  4. Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251-1261. doi:10.1007/s00125-022-05715-4. This systemic review assesses efficacy and safety of tirzepatide for T2DM with different comparators. While many systemic reviews of tirzepatide exist, this specific article has a highly useful graphic to describe the change in HbA1C with different doses in comparison to other GLP-1 RAs, insulin, and placebo; this graphic may be useful for demonstrating HbA1C benefits when describing tirzepatide to patients. Click here to review the article.

References

  1. MOUNJARO (Tirzepatide) Product Monograph. Toronto (ON): Eli Lilly Canada Inc. 2022 Nov 23
  2. Lingvay I, Cheng AY, Levine JA, Gomez-Valderas E, Allen SE, Ranta K, Torcello-Gomez A, Thieu VT. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes Obes Metab. 2023;25(4):965-974. doi:10.1111/dom.14943
 

 

August 29, 2023
Resource Spotlight: Tirzepatide and Upcoming Medications

Latest News

Student Member Stories: Huy Pham

August 29, 2023
 


About Huy 

Pronouns: He/Him
School, Program & Year: University of Toronto, PharmD, fourth year
Social media: @huy_phamacology on Instagram or Huy (Quoc-Huy) Pham on LinkedIn

What is enticing to you about hospital pharmacy?

The aspect that initially enticed me to hospital pharmacy is being able to work on an interprofessional team.

What drew you to join CSHP as a student?

What initially caught my attention as a student was the CSHP Together 2021 Conference. When I read the program for the event, it got me curious and registered for the event and for a membership.

How do you see yourself reflected by CSHP?

I see myself reflected in CSHP through their mission to advance excellence in patient care.

Have you ever attended or presented at a CSHP event?

I've attended the last three National Together Conferences virtually and the Ontario Branch's 2022 Conference. These experiences were very insightful and made me inspired to pursue innovative and high quality patient care.

What is one CSHP resource or benefit that you couldn’t live without?

One CSHP benefit that I probably can't do without is the Pharmacy Residency Application Roadmap course. It provided me a good look at the process and is very helpful with planning out what I'll put in my application.

What is one piece of advice you give soon-to-be pharmacy students?

Always be open to new opportunities. One chance encounter can change the trajectory of your journey.

Anything else you’d like to say to the CSHP members reading this?  

You're doing great. You're all inspirations to us students.

Huy completed a rotation at CSHP national office this spring.

Want to share your student story?
Tell us about yourself here for a chance to be featured.

August 29, 2023
Student Member Stories: Huy Pham

Latest News

Call for Appraisers for the National Awards Program 2023

August 15, 2023



CSHP is seeking award appraisers for the 2023-2024 National Awards Program and the Advanced Pharmacy Practice Residency Award (for pharmacy residents in a Year 2 Program). Award appraisers are critical to the success of these two programs -- your contribution to this process enhances the visibility of excellence in hospital pharmacy practice. To help select this year’s award-winning projects and to help celebrate hospital pharmacy excellence, please consider submitting your name as an appraiser for these awards programs.

Appraisers must be current CSHP members who hold a professional degree in pharmacy and who have been practicing in a hospital or other collaborative healthcare setting for at least five years. However, no prior review or research experience is required. 


National Awards Program

This year's appraisal period will run from November 13 to December 4, 2023

We are seeking appraisers with knowledge in the following areas:

  • Administration/Management 
  • Cardiology 
  • Computers/Technology 
  • Critical Care 
  • HIV/AIDS 
  • Infectious Diseases 
  • Nephrology 
  • Oncology 
  • Palliative Care 
  • Pediatrics 
  • Psychiatry 
  • None of the above (general appraiser)

Advanced Pharmacy Practice Residency Award

The appraisal period will run from January 22 to February 11, 2024. 

We are seeking appraisers to review the major projects of graduates from advanced (Year 2) hospital pharmacy residency programs. To assist with matching projects to knowledgeable reviewers, please indicate your areas of expertise when registering as an appraiser. You may choose from the list above and/or include additional knowledge areas.   


Where possible, submissions are distributed to those knowledgeable in the subject area and appraisers are asked to judge the projects based on contribution to patient care. Please note that appraisers are still able to submit projects for award consideration. In this case, you will be asked to review projects submitted to categories to which you have not applied. 
 
Projects will be assigned to national award appraisers in mid-November and to residency award appraisers in mid-February. You may be asked to review up to three projects during the appraisal period. Award appraisers are asked to volunteer approximately one hour of their time per submission reviewed. For more information, please refer to the Frequently Asked Questions page

To register as an appraiser, please contact Robyn Rockwell, Membership & Awards Administrator, by September 30, 2023 and indicate the following:

  • The awards you wish to review (national, residency, or both)
  • The areas in which you can review
  • Whether you are able to review French submissions

 

August 15, 2023
Call for Appraisers for the National Awards Program 2023

Latest News

Student Member Stories: Holly Wingate

August 10, 2023
 
 

About Holly 

Pronouns: She/Her
School, Program & Year: University of Saskatchewan, PharmD, fourth year
Social media: @HollyMWingate on Instagram

What is enticing to you about hospital pharmacy?

I was initially enticed to hospital pharmacy because it included the parts of pharmacy that I enjoyed most (critically evaluating medications, educating patients, providing recommendations to patients and providers, problem-solving), without the parts I found less enjoyable (explaining the cost of medications to patients who couldn’t afford it, dealing with insurance, having gaps with other health care practitioners due to the main forms of communication being phone or fax). Now, I am more enticed to hospital practice because of the interprofessional approach, where most patient decisions are made as a team with the patient, taking into consideration each profession's expertise, and where communication can be face-to-face. 

What drew you to join CSHP as a student?

As a student, the first thing I knew about CSHP was its involvement in residency programs across Canada and hospital practice information. At the time of joining in my second year of pharmacy, I had seen a friend of mine receive an Interactions newsletter from CSHP via their email, and although I was only starting to seriously consider hospital pharmacy, I knew from this email that CSHP was where I should turn to for this consideration because of the vast resources provided on their website. 

How do you see yourself reflected by CSHP?

I see myself as a student reflected in many areas by CSHP. I see representation in the student delegates who speak for us, the provincial Branches who cater to their students in representing CSHP and offer resources such as mentorships. I especially see representation in the national resources that are more ‘focused’ towards students, for example, the Pharmacy Residency Application Roadmap and the Hospital Pharmacy 101 modules. These resources are created to make the path toward hospital pharmacy that much easier, and for me as a student, that can make all the difference.   

Have you ever attended or presented at a CSHP event?

I attended the virtual CSHP AGM last year for my provincial Branch, and although at home, I felt connected. I knew most of the presenters and award winners and was honored to be able to take part in that moment. I also learned more about my specific Branch and what they had done within the last year, which inspired me to become more involved with my Branch. After this conference, I joined a volunteer board in my Branch to start planning the educational sessions for the next AGM and have since made many bonds I wouldn’t have been able to make without attending that initial conference. 

What is one CSHP resource or benefit that you couldn’t live without?

I really feel I couldn’t live without the Interactions updates and the e-Newsbrief via email. Accessing these updates on my email is one of the first things that got me interested in becoming a CSHP member. This was because I feel there is often so much news to catch up on, and as I am not working in a hospital, it is so easy to fall behind on what is happening in hospital practice. I feel that reading these updates are an easy way to stay connected with the hospital from afar and be a part of the community I hopefully will be a part of post-graduation. These bite-sized pieces of information are perfect for ensuring I am up to date on what's occurring inside hospitals. 

What is one piece of advice you give soon-to-be pharmacy students?

My one piece of advice is to take advantage of what you have offered to you and put yourself out there. Especially with things such as CSHP resources, volunteering opportunities, or being a part of student bodies at your school. The best advice I ever received when I was concerned about applying for things, and my mentor told me "the worst thing that will happen is you get a no, and that in itself will open new doors". So, take a chance and see what happens! 

With CSHP specifically, I think it's worth it to take a few minutes to look at the website and see all that you have available to you and use those resources to further your knowledge of hospital practice, even if you aren't sure what you want to do yet. In your own region, join your local Branch and take on a volunteering role, no matter small or large. Getting involved is a great way to begin your career, even as a student.

Holly completed a rotation at CSHP national office this spring.

Want to share your student story?
Tell us about yourself here for a chance to be featured.

August 15, 2023
Student Member Stories: Holly Wingate

Latest News

Advocacy in Action: August 15

August 15, 2023
 
  

Ongoing, Health Canada Drug Shortages  

 

CSHP is taking action to build a safer, more sustainable, and equitable healthcare system in Canada. Today we dive into an area where CSHP continuously provides expertise at a national level- drug shortages. 

CSHP plays a key role in advocating for mitigation strategies to minimize the impact of drug shortages on Canadians.  
 
We are proud attendees and contributors at federal agency stakeholder meetings. By attending and contributing to these meetings, we help the federal government improve approaches by offering solutions and advice that can make an impact both in the short- and long term. 

Throughout August CSHP has been providing feedback and amplifying the voice of hospital pharmacy on drug shortages. More specifically, on August 2 Rita Dhami, CPO attended a drug shortage meeting on Hydrocortisone Injections. 
 
On August 22, CPO Rita Dhami has been invited to attend a Roundtable on improving access to health products in Canada with the recently appointed Minister of Health, the Hon. Mark Holland.  
 
Additionally, our professional practice team is working on their consultation submission to the Health Canada Drug Shortages Task Force where they will be providing insight into what aspects of healthcare should be invested in for the 2023 budget. They will be commenting on the following four pillars:  

  • Improved communication and transparency 
  • Maintaining an agile regulatory toolbox 
  • Greater supply chain visibility 
  • Enhanced response to supply and demand 

Have a question about Advocacy in Action or CSHP's advocacy and consultation work?
Reach out to our professional practice team!   

August 15, 2023
Advocacy in Action - August 15

Clinical Pearls: New Pharmacotherapy in the treatment of Type 2 diabetes - Tirzepatide

August 11, 2023
By Holly Wingate 
 
This article is part of a series appearing in Interactions, our biweekly newsletter, written and researched by CSHP's students. We've created this series as a valuable learning activity for pharmacy students undertaking rotations at CSHP. Crafting these pieces not only helps students gain in-depth knowledge of specific conditions, treatments, and resources, it also helps them hone their skills in research, critical appraisal, evaluation, synthesis, and writing – all of which will serve them well in clinical practice. The Professional Practice Team works with the students to select hot topics that are of interest and utility to both the students and to you, the reader. We hope you enjoy this piece by one of our future colleagues! Let us know what you think: If you would like to provide any comments or constructive feedback for our students, please email us at practice@cshp.ca.
 

Type 2 Diabetes Mellitus (T2DM) and Obesity: Background

Obesity and T2DM are both defined as chronic diseases by the American Medical Association (AMA), with obesity having been recognized officially in 2013.1 In Canada, the prevalence of obesity has been increased 3-fold since 1985, with an estimated 1.9 million (5%) Canadian adults living with severe obesity in 2016.2 In pediatrics, the prevalence of obesity has also been growing substantially, with ≤26% of 2-17 year olds being overweight and obese.3 Obesity, defined as a BMI >30kg/m2, is a complex condition with many factors interplaying including genetic, behavioral and environmental.2 Obesity poses significant health risks to an individual as excess body fat can alter glucose and metabolism, therefore leading to increased cardiometabolic and cancer risks, and reducing disease-free duration and life expectancy by 6-14 years.This adipose tissue can predispose individuals to many chronic diseases, such as T2DM, among other medical complications.2 On the other hand, T2DM is defined by a lack of insulin creation, insulin resistance, or a mix of both.4 In 2015, approximately 9.3% of Canadians had diabetes; this number is expected to rise to 12.1% by 2025, representing a 44% increase.If not treated properly, complications such as retinopathy, neuropathy, and nephropathy may occur, as well as increased risks for cardiovascular disease.If overweight, weight loss of approximately 5% of an individual's existing body weight may reduce the risk of progression from pre-diabetes to T2DM, thus demonstrating a correlation of T2DM with obesity.Treatments for each condition often overlap with the other, as this Clinical Pearl will demonstrate.

Tirzepatide Background

A new antihyperglycemic known as tirzepatide, was recently approved in November 2022 from Eli Lilly and Company, as the brand name MounjaroTM. It is indicated as a once-weekly subcutaneous injection as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with T2DM. It can be used as monotherapy if metformin was intolerable/inappropriate, or in combination with metformin, a sulfonylurea, a sodium-glucose cotransport-2 inhibitor (SGLT2i), or basal insulin.5

Tirzepatide is a selective glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist (RA), where the GIP receptor activity is similar to endogenous GIP activity, and the GLP-1 receptor activity is lower compared to endogenous GLP-1.5 Prior to tirzepatide, it was thought that GIP had no benefits as a glucose-lowering therapeutic because of observations in T2DM patients.Recently, emerging evidence showed that co-administering GLP-1 and GIP RAs have a synergetic effect resulting in significantly increased insulin and glucagonostatic responses compared to separate administration of each hormone.6 As an incretin analogue, tirzepatide increases insulin secretion, insulin sensitivity, and reduces plasma glucagon levels, all in a dose dependent manner. As it also delays gastric emptying and increases satiety, it is associated with decreased food intake in patients and has shown to reduce fasting and post-prandial glucose levels.5

Place in Therapy for Type 2 Diabetes 

At the time of writing, Eli Lilly and Company is in the process of accumulating tirzepatide stock to supply Canada, therefore it is not currently included in the Canadian Diabetes Guidelines.7,4 However, the American Diabetes Association (ADA) mentions it as a highly effective glycemic-lowering and weight-lowering agent.8 ADA recommends guiding therapy by patient-centered treatment factors, including comorbidities and treatment goals. While tirzepatide treatment will help a patient achieve lower HbA1C and glycemic control goals due to the synergistic GLP-1 and GIP RA effect, other considerations such as weight management goals, if applicable for a patient, need to be assessed. Currently, the highest efficacy for weight loss is seen with tirzepatide and semaglutide.8 In general, tirzepatide is more efficacious than comparators in glycemic control, including HbA1C reductions, and in body weight reductions.While the benefits of tirzepatide are very appealing, cost effectiveness needs to be considered. Though the supply of MounjaroTM has not yet made it to Canada, the Alberta Blue Cross released estimated pricing, which it lists at $12,666 USD per year ($17,170 CAD).12 For reference, semaglutide (WejovyTM) is estimated at $4,726 CAD per year.12 At this time, metformin therapy is still considered first line before add on therapies such as tirzepatide.As trials have only been in patients who are overweight, as defined by a BMI >25kg/m2, tirzepatide is recommended if a patient is overweight and in need of HbA1C reductions, and who are in a financial position to be able to afford tirzepatide as there is no provincial, territorial, or NIHB coverage at the time of writing.11

Evidence for Type 2 Diabetes

Five main SURPASS trials were used to obtain drug approval for tirzepatide and are summarized below (see Table 1).13 In the trials, tirzepatide showed more benefits for achieving glycemic control, including reductions in HbA1C and blood glucose control, with varying degrees of weight loss and without hypoglycemia; this was seen with monotherapy, in combination with metformin, an SGLT2i, or basal insulin, and when comparing placebo, semaglutide, and basal insulin.13 

Table 1: SUPRASS 1-5 Trials

To note, SURPASS-J-Mono compared tirzepatide to dulaglutide and showed very similar results to SURPASS-2, with Tirzepatide having more HbA1C and bodyweight reductions, and no significant hypoglycemia.5,23 SURPASS-J-Combo was a safety trial which monitored tirzepatide use in participants taking other anti-hyperglycemic medications to assess serious adverse events (SAE), defined as death, hospitalization, life-threatening experiences, persistent or significant disabilities, birth defects, or medical events that jeopardize the participant, at any point from baseline through to week 52.24 Only 2 SAE’s as defined above occurred; no participants experienced mortality.24


SURPASS-CVOT is comparing tirzepatide to dulaglutide on MACE in participants with T2DM and atherosclerotic cardiovascular disease for 54 months and will be completed in October 2024.25 The primary outcome is looking at time to first occurrence of death from cardiovascular causes, myocardial infarction or stroke.25 Finally, SURPASS-6 trial concluded in November of 2022, but has no results posted. SURPASS-6 aimed to compare safety and efficacy of tirzepatide to insulin lispro and insulin glargine, with primary outcome being the mean change in HbA1C from baseline to 52 weeks.26 

On the Horizon: Indication for Obesity (SURMOUNT)

SURMOUNT-1 was a placebo-controlled trial that looked at tirzepatides effect on body weight in people living with obesity without T2DM, as defined by a BMI≥30kg/m2, and those who are overweight, as defined by a BMI≥27 kg/m², with weight-related comorbidities.27  This study has two phases: the main phase, and an extension phase for participants with pre-diabetes.27 The main phase lasted 72 weeks, and the extension phase is continuing for 2 more years. The primary outcomes include percent change in body weight, and percent of participants achieving ≥5% body weight reduction.27 At the end of the main phase, tirzepatide at any dose had more percent changes in body weight compared to placebo, and more participants achieving ≥5% body weight reduction (5mg: 89.4%, 10mg: 96.1%, 15mg: 96.3% vs. Placebo 27.8%). When assessing ≥20% body weight reduction as a secondary outcome, the 10mg and 15mg tirzepatide groups had 55% and 62.8% of participants achieving this, respectively.27

There are many ongoing SURMOUNT trials. SURMOUNT-2 looks at tirzepatide in participants with T2DM who have obesity or are overweight (BMI≥30kg/m2 or BMI≥27kg/m2), with primary outcomes looking at the percent change in body weight, and number of participants with a ≥5% body weight reduction from baseline to 72 weeks.28 SURMOUNT-3 looks at how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program with the same primary outcomes as SURMOUNT-2.29 SURMOUNT-4 looks at how tirzepatide maintains its body weight loss; the lead-in phase of this trial is when participants with obesity will take tirzepatide.30 Then, participants will be randomized at week 36 to either continue tirzepatide or switch to placebo for the rest of the trial. The primary outcome is the percent change in body weight from week 36-88.30Finally, SURMOUNT-J looks at how tirzepatide affects body weight with a low-calorie diet and physical activity in participants with obesity.31 The primary outcomes include percent change in body weight and participants achieving ≥5% body weight reduction from baseline to 72 weeks.31 

Looking further: Heart Failure with Preserved Ejection Fraction (HFpEF) (SUMMIT)

The SUMMIT trial began in April 2021, and will be completed in July 2024. This trial looks at tirzepatide in participants with HFpEF, as defined by ejection fraction ≥50% and a diagnosis of stable heart failure.32 This trial excludes patients with HbA1C >9.5%, among other criteria.32  There are two primary outcomes, including a composite outcome of all-cause mortality, heart failure events, 6-minute walk test distance (6MWD) and Kansas City cardiomyopathy questionnaire clinical summary score (KCCQ CSS)32. The second outcome is a change in exercise capacity as measured by 6MWD from baseline to week 52.32  

Ongoing Trials: Pediatric Populations

Eli Lilly and Company began a placebo-controlled trial of tirzepatide in pediatric patients 10-18 years old, for the treatment of T2DM inadequately controlled with metformin, basal insulin or both, as defined by an HbA1C of 6.5-11%, in April 2022.33 This trial is still ongoing; therefore, no results have been posted. The primary outcome is the change in HbA1C from baseline to week 30.33 There is also an active phase 1 trial that will be completed in July 2024, which is evaluating the pharmacokinetics, safety, and tolerability of tirzepatide in pediatric patients 6-11 years old with obesity, as defined by a BMI greater than the 95th percentile for a participants age and sex.34 The primary outcome is the number of participants with at least one treatment emergent or serious adverse event from baseline to week 13.34 

Drug specific Information

Tirzepatide has important drug specific characteristics that are summarized below (see Table 2). Refer to the MounjaroTM. Product Monograph for more detailed information, including patient monitoring. 

Table 2: Tirzepatide Information

Hospital Pharmacy Considerations

As research shows, the synergy of GLP-1 and GIP RA actions lead to significant benefits for HbA1C, fasting and postprandial glucose levels, insulin sensitivity and body weight reductions.36  We do not have guidelines indicating where tirzepatide use will land in respect to other anti-hyperglycemic medications for T2DM, however, we do know non-pharmacologic measures and metformin should be tried prior to tirzepatide, especially with its cost. It is difficult to articulate where to place tirzepatide in comparison with semaglutide or other GLP-1 RA’s, therefore at this time tirzepatide use remains patient specific. Based on trial data, tirzepatide is ideal for patients who are overweight with a BMI>25kg/m2 , in need of HbA1C reductions, and who are in a financial position to be able to afford tirzepatide, as there is no private or public coverage at the time of writing, and no way of predicting if such coverage will come.12   

At this time, it is unknown if tirzepatide will receive coverage on the hospital formulary, therefore if a patient who is taking once weekly tirzepatide injections is admitted to the hospital, and is to continue therapy, they will need to use their own supply. However, if a patient experiences severe nausea or diarrhea from treatment and is extremely ill, sick day management may include discontinuing tirzepatide to decrease the risk of acute kidney injury from dehydration.5  In the event a patient has missed their scheduled tirzepatide dose for less than four days, tirzepatide can be given as normal in hospital.5 If it has not been continued in hospital for a patient with diabetes, sliding scale insulin can be used in the interim, as would normally occur in hospital. Substituting a different GLP-1 RA in tirzepatide’s place, such as semaglutide, may make pharmacological sense, although there is no data describing titration in this instance, nor is there evidence for this substitution. This decision is entirely patient and situation specific.  

Predicting how tirzepatide will be used in T2DM in Canada is variable, especially as we await supply. The upcoming SURMOUNT and SUMMIT trial results may determine tirzepatide’s future in Canada.  

References

  1. Recognition of Obesity as a Disease H-440.842. The American Medical Association (AMA); 2023. Available from: https://policysearch.ama-assn.org/policyfinder/detail/obesity?uri=%2FAMADoc%2FHOD.xml-0-3858.xml 
  2. Wharton S, Lau D, Vallis M, Sharma A, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. Canadian Medical Association Journal. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707 
  3. About Active Kids, Healthy Kids. Canadian Paediatric Society; 2022. Available from: https://cps.ca/en/active-actifs/about-active-kids-healthy-kids 
  4. Diabetes Canada Clinical Practice Guidelines. Diabetes Canada; 2022. Available from: https://guidelines.diabetes.ca/cpg/ 
  5. MOUNJAROTM (Tirzepatide) Product Monograph. Toronto (ON): Eli Lilly Canada Inc. 2022 Nov 23 
  6. Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2021;12(1):143–157. doi:10.1007/s13300-020-00981-0 
  7. Customer Service, Eli Lilly and Co.; May 15, 2023. Available at: Ph. 1(888) 545-5972. 
  8. Pharmacologic Approaches to Glycemic Treatment: Standards of Care. The Journal of Clinical and Applied Research and Education: American Diabetes Association 2023; 46(9), 148-158. Available from: https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/46/supplement_1/ 13/standards-of-care-2023-copyright-stamped-updated-120622.pdf 
  9. A Study of Tirzepatide (LY3298176) versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes (SURPASS-2). Eli Lilly and Company; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT03987919  
  10. Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251–1261. doi:10.1007/s00125-022-05715-4 
  11. McDonald A, Farrah K. Tirzepatide for Type 2 Diabetes Mellitus: Emerging Health Technologies. CADTH Horizon Scan; 2022 Jan. Available from: https://canjhealthtechnol.ca/index.php/cjht/article/view/eh0104/655  
  12. Drug Pipeline in 2023: Notable drugs. Alberta Blue Cross; 2023. Available from:  https://www.ab.bluecross.ca/plans/group/drug-pipeline-2023.php  
  13. Lingvay I, Cheng AY, Levine JA, Gomez-Valderas E, Allen SE, Ranta K, et al. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes Obes Metab. 2023;25(4):965-974. doi:10.1111/dom.14943 
  14. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6 
  15. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide (LY3298176) in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Eli Lilly and Company; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT03954834  
  16. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England journal of medicine. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519 
  17. Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet (London, England). 2021;398(10300): 583–598. doi:10.1016/S0140-6736(21)01443-4 
  18. A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes (SURPASS-3). Eli Lilly and Company; 2022. Available from:  https://clinicaltrials.gov/ct2/show/NCT03882970  
  19. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet (London, England). 2021;398(10313):1811–1824. doi:10.1016/S0140-6736(21)02188-7 
  20. A Study of Tirzepatide (LY3298176) Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). Eli Lilly and Company; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03730662  
  21. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534–545. doi:10.1001/jama.2022.0078 
  22. A Study of Tirzepatide (LY3298176) Versus Placebo in Participants with Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin (SURPASS-5). Eli Lilly and Company; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04039503  
  23. A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants with Type 2 Diabetes (SURPASS-J-mono). Eli Lilly and Company; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03861052  
  24. A Long-term Safety Study of Tirzepatide (LY3298176) in Participants with Type 2 Diabetes (SURPASS-J-combo). Eli Lilly and Company; 2022. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03861039  
  25. A Study of Tirzepatide (LY3298176) Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT). Eli Lilly and Company; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04255433  
  26. A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6). Eli Lilly and Company; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04537923  
  27. A Study of Tirzepatide (LY3298176) in Participants with Obesity or Overweight (SURMOUNT-1). Eli Lilly and Company; 2023. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04184622  
  28. A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2). Eli Lilly and Company; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04657003  
  29. A Study of Tirzepatide (LY3298176) in Participants After A Lifestyle Weight Loss Program (SURMOUNT-3). Eli Lilly and Company; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04657016  
  30. A Study of Tirzepatide (LY3298176) in Participants with Obesity or Overweight for the Maintenance of Weight Loss (SURMOUNT-4). Eli Lilly and Company; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04660643  
  31. A Study of Tirzepatide (LY3298176) in Participants with Obesity Disease (SURMOUNT-J). Eli Lilly and Company; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04844918  
  32. A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT). Eli Lilly and Company; 2023. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04847557  
  33. A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (SURPASS-PEDS). Eli Lilly and Company; 2023. Available from: https://clinicaltrials.gov/ct2/show/study/NCT05260021 
  34. A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity. Eli Lilly and Company; 2023. Available from: https://clinicaltrials.gov/ct2/show/study/NCT05696847 
  35. Frias JP, Nauck MA, Van J, Benson C, Bray R, Ciu X, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938–946. doi:10.1111/dom.13979 
  36. Bastin M, Andreelli F. Dual GIP-GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential. Diabetes, metabolic syndrome and obesity: targets and therapy. 2019;12:1973–1985. doi:10.2147/DMSO.S191438  

 

Latest News

August 11, 2023
Clinical Pearls: New Pharmacotherapy in the Treatment of Type 2 Diabetes - Tirzepatide

Latest News

Sustainability in Pharmacy Task Force Recommendations Consultation Request

August, 2023
 
 
 
In January 2023, the CSHP Board struck a task force to research, identify and prioritize goals to address the climate change crisis.  The CSHP Sustainability in Pharmacy Task Force has led this work with significant collaboration from the Canadian Association of Pharmacy for the Environment (CAPhE). The draft recommendations are available for review and comment. Review the attached document ‘CSHP Sustainability in Pharmacy Recommendations’ and complete the survey: https://ubc.ca1.qualtrics.com/jfe/form/SV_cu6rgu0mynTW9EO.

Survey will be available until: Aug 25th, 2023. It will take approximately 20-30 minutes to complete.

Thank you for your participation in this important work! For any questions related to the survey, please reach out to our Co-Chairs Karen Dahri (karen.dahri@vch.ca) or Kristen Tangedal (kirsten.tangedal@saskhealthauthority.ca). 
August 01, 2023
Sustainability in Pharmacy Task Force Recommendations Consultation Request

Latest News

CPRB News - August 2023

August 1, 2023
 
 
 
PRAMS survey results and 2023-24 application cycle updates - August 2023

Thank you to all those from across the country who responded to this year's PRAMS user survey. Your responses regarding working with international pharmacy graduates and the handling of equity-related data will go on to inform PRAMS' policy work going forward. 

Application form refinements include a reduction of applicant information input (e.g., only allowing applicants to list an entry once for placements/ work/ volunteer/ leadership/ extracurricular curricular experiences), eliminating duplicate data (e.g., asking only for pharmacy transcripts to be uploaded, reducing entry of addresses), and updating language to align with current practice.  These refinements streamline the form for applicants and make the application more succinct for programs. Updates to the referee form will include mandatory comments, referee contact information, and asking for referees to comment on the applicant’s opportunities for growth.  A sample application with all updates will be available in August to allow programs to prepare for applicant screening and interviewing.  

Based on feedback from programs and applicants, the CPRB voted to remove the ability for programs to see other programs to which applicants applied with the goal to avoid disadvantaging any applicant. This functionality will be removed for the upcoming application cycle. 

The applicant fee structure has been updated to $275 for 5 programs, and any additional program will have a cost of $25 per program. 
 
Dates of note for the 2023/2024 application cycle are as follows:
  • July 31, 2023 – Programs to provide updated information for PRAMS 
  • August 7, 2023 – PRAMS opens to applicants 
  • October 13, 2023 – PRAMS closes to applicants and applications available to programs 
  • January 5, 2024 – Ranking deadline for applicants and programs 
  • January 9, 2024 – Match results available 
August 01, 2023
CPRB News - August 2023

Latest News

Advocacy in Action: August 1

August 1, 2023
 
 

June 6, Choosing Wisely Canada

CPO Rita Dhami and Practice Specialist Kiet-Nghi Cao participated in the Annual Meeting of the Societies with key partners across multiple disciplines. The focus of this year’s meeting was on sustainable practices. 

June 16, Health Canada Health Products Supply Chain Advisory Committee with Health Minister Duclos

CEO Jody Ciufo and Rita Dhami shared insights on drug shortage solutions.

June 19, NAPRA Pharmacy Practice Meeting  

Rita Dhami and CSHP Vision Task Force Lead Mary Gunther participated in a valuable engagement session with key partners across the pharmacy sector on the implementation of the NAPRA Principles of Professionalism into pharmacy practice. 

July 27, Health Canada/Public Health Agency of Canada Pharmaceutical Drugs Program (PDP)   

CPO Rita Dhami was able to share CSHP perspectives with PHAC on drug shortages, assessment of climate change impacts, and the National Pharmacare Strategy.  

Ongoing, Health Canada Drug Shortages  

CSHP is providing weekly feedback and amplifying the voice of hospital pharmacy on drug shortages. 


CSHP is taking action to build a safer, more sustainable, and equitable healthcare system in Canada. Through active engagement in various committees, forums, and partnerships, CSHP strives to address drug shortages, enhance pharmaceutical safety, advance a National Pharmacare Strategy, promote pharmacy professionalism, and embrace sustainable practices. 

Addressing Drug Shortages

CSHP plays a key role in advocating for mitigation strategies to minimize the impact of drug shortages on Canadians. We are proud attendees and contributors at federal agency stakeholder meetings. We offer solutions and advice to the federal government on how they can best alter and implement their approaches in both the short and long term. CPO Rita Dhami has offered feedback on the federal government’s Pharmaceutical Drugs Program (PDP). She recognized the role PDP has in maintaining the safety, efficacy, and quality of regulation and while it has also vastly improved transparency in areas like regulatory processes or drug supply, there is still work to be done. Namely, she identified the opportunity for early identification of supply chain disruptions and for shortening the runway of foreign supply. The focus on drug shortages is likely to soon expand to other shortages in the health care industry, including medical equipment and nutritional supplements. 

Advancing National Pharmacare Strategy

It has long been CSHP’s belief that the Canadian healthcare system must be restructured so that Canadians have equitable access to evidence-based, effective, medically necessary drugs, including access to the expertise of pharmacists, regardless of their care setting or their ability to pay. This stance was affirmed by CPO Rita Dhami in her recent discussions with Health Canada/Public Health Agency of Canada, where she advocated for a transparent National Pharmacare Strategy that harmonizes access and coverage of drugs across Canada. 

Integrating Professionalism Principles into Pharmacy Practice

We have aligned ourselves with the need for professionalism in pharmacy practice as set out by the National Association of Pharmacy Regulatory Authorities (NAPRA). The embracing of professionalism not only improves the working conditions for pharmacy team members but also improves the level and the quality of care that health care practitioners can offer their patients. We have offered our perspective on how it can assist in the dissemination, uptake, and implementation of these principles in the daily work of collaborative healthcare environments especially as they align with the mission of CSHP’s Vision for Pharmacy Task Force. CSHP looks forward to further communication and collaboration on this topic. 

Promoting Sustainable Pharmacy Practices

CSHP is dedicated to promoting sustainable practices within the health care sector. 
 
CSHP continues to accomplish this goal through attending stakeholder meetings where we can amplify our current efforts and advocacy for sustainability in pharmacy, including the push for the assessment of climate change impacts in the regulatory process in addition to highlighting the work of CSHP’s Sustainability task force. These meetings provide CSHP insight into our healthcare peers sustainability activity. We take away inspiration and concepts to apply to hospital pharmacy.  
 
Soon, CSHP will be refreshing our Choosing Wisely Canada Hospital Pharmacy recommendations. These updated recommendations will balance quality pharmacy practice as well as environmental consciousness and will include a ‘green leaf’ label where sustainability practices are in play. 

Have a question about Advocacy in Action or CSHP's advocacy and consultation work?
Reach out to our professional practice team!   

August 01, 2023
Advocacy in Action - August 1

Latest News

Apply now for the William McLean Innovation Grant (NEW)

July 11, 2023



The William McLean Innovation Grant will support the development, implementation or testing of an innovative pharmacy practice program/model, service or technology that is aimed at improving patient care and outcomes. Knowledge translation activities for a previously developed innovation in patient care program/model, service or technology will also be considered. An example of this would be to expand pharmacist dosing of vancomycin to site within a health care region. This grant has been made possible by a bequest from the Estate of William McLean.

Eligibility Criteria

  • Applicant must be a CSHP Member, Member-in-Training, or Student Supporter for at least 12 months at the time of the grant application.
  • Grant applicants or a specific project can only receive this grant once.
  • Application does not duplicate funding already held for a grant from the CSHP Foundation and has not received a grant in the past two years.
  • The following activities are not eligible for the William McLean Innovation Grant: research studies; infrastructure; technology; and travel.
  • Direct costs associated with the development and implementation of the project will be considered eligible, which may include the salary of pharmacist, pharmacy technician, pharmacy student or technical support.
  • The timeline for the completion of the project shall not exceed 18 months (grant funds provided to successful submission(s) early May 2024 and project start date should be shortly thereafter).

Submission Requirements

  • Project summary (maximum 2,000 words) including problem statement, significance, potential impact of pharmacy practice, anticipated results, evaluation plan, knowledge translation activities, team composition and project end date.
  • Project budget - list project expenses correlated with your proposal. Ensure all items are listed and costed (use budget template provided, see link below). 
  • CV of Principal Applicant.

Maximum grant allotment: $5,000/year
Grants will be ranked and funded until the $5,000 allotment is reached. Applications will be reviewed by the Foundation’s Education Grant Committee. 

Projects will be evaluated on:
Potential to impact pharmacy practice / Relevance: potential to lead to desired outcome / Innovation: More than an incremental improvement over current approach / Sustainability: Is the project sustainable / Evaluation: Evaluation plan is reasonable given scope of project / Transferable: Would other pharmacists/practice settings be able to utilize this innovation / Project Execution plan: Is plan reasonable/feasible / Budget (use budget template provided)

 

DEADLINE FOR SUBMISSIONS: November 30, 2023
Website link: https://cshp-scph.ca/william-mclean-innovation-grant
Submissions are to be sent to Rosemary Pantalone, CSHP Foundation Administration, at rpantalone@cshp.ca
All files should be in PDF format. 
Grant decisions will be announced late March 2024

July 12, 2023
Apply now for the William McLean Innovation Grant (NEW)

Latest News

Resource Spotlight: Hypertensive Crises

July 13, 2023
 

Written by Huy Pham

This article was written and researched by a CSHP student member for Interactions, our biweekly newsletter. Crafting these pieces not only helps students gain in-depth knowledge of specific conditions, treatments, and resources, it also helps them hone their skills in research, critical appraisal, evaluation, synthesis, and writing – all of which will serve them well in clinical practice. The Professional Practice Team works with the student to select topics that are of interest and utility to both the student and to you, the reader. We hope you enjoy this piece by one of our future colleagues! Let us know what you think: If you would like to provide any comments or constructive feedback for our students, please email us at practice@cshp.ca

Background 

Hypertensive crisis is an acute elevation in blood pressure and can be classified based on whether end-organ damage is absent (hypertensive urgency) or present (hypertensive emergency). While hypertensive urgencies require gradual blood pressure reduction by starting, restarting, or intensifying antihypertensive therapy, hypertensive emergencies require prompt treatment to prevent or limit further worsening of end-organ damage. This “Resource Spotlight'” provides links to help pharmacists learn more about hypertensive crises, the differences between hypertensive urgencies and hypertensive emergencies, and the treatments of hypertensive emergencies. To learn more about hypertensive crises and their management, check out CSHP's recent Clinical Pearls on Hypertensive Crises.

Hypertension Canada

Hypertension Canada is a national non-profit organization whose mission is to enable detection, prevention and management of hypertension and the associated complications to advance health. Their website contains resources to help pharmacists with educating patients on blood pressure management such as log sheets to record home blood pressure results and brochures that give the patient an overview of hypertension and its management. They also offer a professional certification program for pharmacists to help develop the knowledge and confidence needed to assess and manage hypertension. Hypertension Canada has a clinical guideline that provides recommendations on the assessment and diagnosis of hypertension, preventative measures, and the appropriate antihypertensive therapy for management. Hospital pharmacists may use the latter to optimize the patient’s antihypertensive therapy during their stay and post-discharge.

American College of Cardiology/American Heart Association Task Force Guidelines

American College of Cardiology/American Heart Association (ACA/AHA) Task Force has published a guideline on the prevention, detection, evaluation, and management of hypertension. The writing process involves clinicians and representatives from many organizations including the American Pharmacists Association. Section 12.2 outlines their recommendations for the management of hypertensive crises and the preferred pharmacotherapy for hypertensive emergencies based on the compelling indications. It should be noted that one of the drugs discussed in the guideline, fenoldopam, is currently not available in Canada.

European Society of Cardiology

The European Society of Cardiology (ESC) Council released a position paper on hypertensive emergencies. This position describes malignant hypertension, which they define as  a hypertensive emergency that is characterized by the presence of advanced retinopathy. It also provides proposals for diagnostic studies to investigate suspected hypertensive emergencies, as well as for the acute management depending on clinical presentation.

British and Irish Hypertension Society Position Paper

The British and Irish Hypertension Society (BIHS) published a recent position paper on the epidemiology, diagnosis, and management of hypertensive crisis. The paper classified hypertensive crisis into three categories based on pathophysiology: acute severe hypertension (their preferred term for hypertensive urgencies), hypertensive emergency, and malignant/accelerated hypertension. The BIHS do not consider malignant/accelerated hypertension to be a “true” hypertensive emergency and recommends that it be treated with oral calcium channel blockers or beta-blockers for a gradual reduction in blood pressure if there are no other co-existent organ damage. 

Published Literature

A 2-part clinical review by Rhoney and Peacock called “Intravenous therapy for hypertensive emergencies” discusses the IV antihypertensive drugs that may be used in patients with hypertensive emergencies. Part 11 covers the pharmacology and mechanism of actions of the drugs, associated adverse effects and contraindications, and practical considerations. Part 22  outlines their comparative efficacies and safety and an overview of the clinical evidence relating to their use in addressing the end-organ complications associated with hypertensive emergencies. Although the review was published in 2009, the drugs discussed in the review are recommended by the ACA/AHA, ESC, and BIHS for the management of hypertensive emergencies. 

Review articles by Miller et al.3 (“Hypertension Management in Emergency Departments”) and by Brathwaite and Reif.4 (“Hypertensive Emergencies: A Review of Common Presentations and Treatment Options”) provide outlines of the management of and treatment considerations in hypertensive emergencies. These may be useful for pharmacists in developing goals of therapy and a therapeutic care plan.

An article5 in the Journal of the American Heart Association (“Malignant Hypertension: Current Perspectives and Challenges”) discusses the diagnosis and treatment of malignant hypertension. It outlines some of the uncertainties surrounding the determination of the incidence and prevalence of malignant hypertension, the ideal therapeutic approaches, and possible biomarkers that aid in risk assessment, diagnosis and monitoring.

References

  1. Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 1. Am J Health Syst Pharm. 2009 Aug 1;66(15):1343–52.
  2. Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 2. Am J Health Syst Pharm. 2009 Aug 15;66(16):1448–57.
  3. Miller J, McNaughton C, Joyce K, Binz S, Levy P. Hypertension Management in Emergency Departments. Am J Hypertens. 2020 Apr 20;33(10).
  4. Brathwaite L, Reif M. Hypertensive Emergencies. Cardiol Clin. 2019 Aug;37(3):275–86.
  5. Boulestreau R, van den Born BH, Lip GYH, Gupta A. Malignant Hypertension: Current Perspectives and Challenges. J Am Heart Assoc. 2022 Apr 5;11(7).

July 11, 2023
Resource Spotlight: Hypertensive Crises

Latest News

CPRB News - July 2023

July 11, 2023
 
 
Standards Group Updates - July 2023

The Standards Subgroup is made up of the following volunteers: Henry Halapy (co-chair), Debbie Kwan (co-chair), Aleisha Enemark, Nicole Bruchet, Mike Legal, Rhonda Rhoedler, Brendan Mitchell, and Janice Yeung.  Katherine Desforges will join the group starting in September.  Henry Halapy will be finishing his term as the Standards Subgroup co-chair, with Mike Legal starting as the new co-chair in September.  

The group has worked on updates to the 2018 Year 1 and 2016 Year 2 Standards over the last year.  These 2023 updates are now posted and programs have one year to implement the updated Standards.  Highlights of the changes include: clarity on assessments of resident personal learning objectives, clarity on the documentation of residents achieving competencies, and clarity around the utilization of external training sites.  In addition, for Year 2 programs, clarity on the utilization of rotations outside of the defined area of practice.
 
July 11, 2023
CPRB News - July 2023

No content found

No content found

No content found

No content found

No content found

No content found

No content found